Abvc Biopharma (ABVC) Common Equity (2010 - 2026)

Abvc Biopharma (ABVC) has reported Common Equity for 17 consecutive years, with $12.3 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Common Equity rose 29.29% year-over-year to $12.3 million; the trailing twelve-month figure through Jun 2026 stood at $12.3 million (up 29.29% YoY), and the FY2025 full-year result was $13.3 million, up 1736.77% from the prior year.
• Common Equity retreated to $12.3 million in Q2 2026 per ABVC's latest filing, from $12.8 million in the prior quarter.
• Across five years, Common Equity topped out at $14.5 million in Q3 2025 and bottomed at $723959.0 in Q4 2024.
• Historically, Common Equity has averaged $6.3 million across 5 years, with a median of $6.5 million in 2022.
• The sharpest annual moves came in 2023 and 2025: Common Equity slumped 85.16% in 2023, then jumped 1736.77% in 2025.
• Over 5 years, Common Equity stood at $1.4 million in 2022, then retreated by 7.45% to $1.3 million in 2023, then plunged by 42.24% to $723959.0 in 2024, then surged by 1736.77% to $13.3 million in 2025, then retreated by 7.73% to $12.3 million in 2026.
• According to Business Quant data, Common Equity over the past three periods registered $12.3 million, $12.8 million, and $13.3 million for Q2 2026, Q1 2026, and Q4 2025 respectively.